



HCV DRAG Definitions Working Group DNWG

This group was conceived at the 5th HCV DRAG meeting in Boston, 2010 is a collaboration between the HCV DRAG, IDSA, EASL and AASLD and will help bring uniformity and clarity to the terms and definitions currently being used in DAA clinical trials. Since the DAA trials field is in its infancy, the WG will regularly update these terms as the field evolves. A manuscript regarding this topic is currently being drafted.

James Appleman, PhD

Anadys Pharmaceuticals, Inc.

Jordan Feld, MD, MPH

Toronto Western Hospital Liver Center

Patrick Harrington, PhD

U.S. Food and Drug Administration

Mingjun Huang, PhD

Achillion Pharmaceuticals, Inc.

Ira Jacobson, MD

Cornell University

Filip Josephson, MD, PhD

Swedish Medical Products Agency/European Medicines

Dale Kempf, PhD

Abbott Laboratories

Ann Kwong, PhD

Vertex Pharmaceuticals

Nina Mani, PhD, MPH

Forum for Collaborative HIV Research

Jeffrey Murray, MD, MPH

U.S. Food and Drug Administration

Isabel Najera, PhD

Hoffmann La Roche

Richard Colvin, MD, PhD

Novartis Institutes for BioMedical Research, Inc.

Xavier Forns, MD, PhD

Hospital Clinic

Gabrielle Heilek, PhD

Roche Molecular Systems

Eric Hughes, MD, PhD

Bristol-Myers Squibb

Donald M. Jensen, MD, FACP

University of Chicago Medical Center

Minhee Kang, PhD

Harvard School of Public Health

Tara Kieffer, PhD

Vertex Pharmaceuticals

Geert Maertens, PhD

Biocartis SA

Veronica Miller, PhD

Forum for Collaborative HIV Research

Lisa Naeger, PhD

US Food and Drug Administration

Gaston Picchio, PhD

Janssen research and Development, LLC



Forum for Collaborative HIV Research

Stuart Ray, MDJohns Hopkins University

Stephen Rossi, PharmD

Jerry Stern, MDBoehringer Ingelheim Pharmaceuticals, Inc.

Tracy SwanTreatment Action Group

Prasad Velisetty, MD
Quintiles Global CRO

Heiner Wedemeyer, MDMedizinische Hochschule Hannover

Stuart Ray, MD Johns Hopkins University

Stephen Rossi, PharmD Gilead

Jerry Stern, MDBoehringer Ingelheim Pharmaceuticals, Inc.

Tracy Swan
Treatment Action Group

Prasad Velisetty, MD Quintiles Global CRO

Heiner Wedemeyer, MDMedizinische Hochschule Hannover

Stefan Zeuzem, MDJ.W. Goethe University Hospital

Jacqueline Reeves, PhD

Monogram Biosciences

Kenneth Sherman, MD, PhD University of Cincinnati

John Sullivan-Bolyai, MD, MPH Idenix Pharmaceuticals

Andrew Talal, MD, MPH
Weil Medical College of Cornell University

John Ward, MDCenters for Disease Control and Prevention (CDC)

Stephen Worland, PhD Anadys Pharmaceuticals, Inc.

Jacqueline Reeves, PhD Monogram Biosciences

Kenneth Sherman, MD, PhD University of Cincinnati

John Sullivan-Bolyai, MD, MPH Idenix Pharmaceuticals

Andrew Talal, MD, MPH Weil Medical College of Cornell University

John Ward, MD
Centers for Disease Control and Prevention (CDC)

Stephen Worland, PhD Anadys Pharmaceuticals, Inc.